Avacta Group PLC - AIM-listed developer of Affimer biotherapeutics and reagents - the AffiDX SARS CoV-2 rapid antigen test is confirmed to be able to detect the new dominant variants of the coronavirus, known as the B117, or Kent variant, and the D614G variant.
"We are pleased to confirm that Avacta's rapid antigen test detects the B117 strain, an important variant of the SARS-CoV-2 virus and one which is especially prevalent in the UK. We have also shown that our test detects the D614G variant, the current dominant global strain," notes Chief Executive Alastair Smith.
Current stock price: 217.00 pence, closed up 9.1% on Monday
Year-to-date change: up 90%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Avacta Group (AVCT)